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Abstract
Background: Global deregulation of DNA methylation is one of the crucial causes of hepato cellular carcinoma
(HCC). It has been reported that the anti-cancer drug 5-azacytidine (5-AZA) mediates the activation of tumor
suppressor genes through passive demethylation by inhibiting DNMT1. Recent evidence suggests that active
demethylation which is mediated by ten-eleven translocation (TET) proteins may also be an important step to
control global methylation. However, there exists a controversial discussion in which TET proteins are involved in
the demethylation process in HCC. Therefore, we firstly wanted to identify which of the TETs are involved in
demethylation and later to study whether or not 5-AZA could trigger the TET-dependent active demethylation
process in HCC. HCC cell lines (Huh-7, HLE, HLF), primary human hepatocytes (hHeps), and tissues from both healthy
(55 patients) and HCC patients (55 patients) were included in this study; mRNA levels of isocitrate dehydrogenase
(IDH1, 2) and TETs (TET1–3) were studied via qPCR and confirmed by Western blot. The expression of 5hmC/5mC was
determined by immunohistochemistry in human HCC tissues and the corresponding adjacent healthy liver. HCC cell
lines were stimulated with 5-AZA (0–20 μM) and viability (Resazurin conversion), toxicity (LDH release), proliferation
(PCNA), and 5hmC/5mC distribution were assessed. In addition, knockdown experiments on TET proteins in HCC cell
lines using short interference RNAs (siRNAs), in the presence and absence of 5-AZA, were performed.
Results: Our data applying qPCR, immunofluorescence, and Western blotting clearly show that TET2 and TET3 but not
TET1 were significantly decreased in HCC tissue and different HCC cell lines compared to non-tumor liver tissues and
hHeps. In addition, we show here for the first time applying knockdown experiments that 5-AZA is able to trigger an
active TET2-dependent demethylation process with concomitant significant changes in 5hmC/5mC in HCC cell lines
and hHeps.
Conclusions: Our data clearly show that the expression and activity of TET2 and TET3 proteins but not TET1 are
impaired in hepatocellular carcinoma leading to the reduction of 5hmC in HCCs. Furthermore, this study identified a
novel function of 5-azacytidine in promoting a TET-mediated generation of 5hmC suggesting that the availability of
5-AZA in cancer cells will have various effects on different epigenetic targets. These findings may open new
therapeutic strategies for epigenetic drugs to treat HCC.
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Background
In the past years, epigenetic studies have focused on
DNA methylation in mammals. DNA methylation plays
an important role in genomic imprinting, especially in
the inactivation pattern of X-chromosome [1, 2], the si-
lencing of retrotransposon, and activation of tissue-spe-
cific genes. Recently, it has been demonstrated that these
epigenetic changes have an influence in various patholo-
gies and gene therapies, for instance, in cancer [3], viral
infections [4], and the activity of mobile elements [5].
Methylation at the C-5 position of cytosine (C) has long
been considered to be the only biologically functional epi-
genetic modification of the animal genomic DNA. In
mammalians, 5-methylcytosines (5mC) established by
DNA methyltransferases (DNMTs), mainly at CpG dinu-
cleotides, is associated with gene repression [6–8].
Loss of methylation was observed during the develop-
ment processes. Therefore, it was suggested that DNA
methylation is reversible either through passive demeth-
ylation via DNA replication or by active demethylation
via DNA repair followed by base excision repair of
modified nucleotides or DNA glycosidase [9–11]. More-
over, it has been shown in many studies that active de-
methylation does occur in many mammalian cells [12].
The most well-known example is the rapid loss of 5mC
immunoreactivity of the paternal pronucleus in the zyg-
ote after fertilization [13]. The active DNA demethyla-
tion pathway is enabled by the ten-eleven translocation
proteins (TETs), named after the ten-eleven transloca-
tion (q22, q23) (10, 11) occurring in rare cases of acute
myeloid and lymphocytic leukemia, which all belong to
the family of Fe(II)/2-oxyglutarate-dependent dioxy-
genases [9, 14]. 5mC is oxidized by TET proteins and
thereby converted to 5hmC, 5fC, and 5CaC [9, 15]. TET
proteins mediate the DNA demethylation process and
increase the diversity of the epigenetic state of genomic
DNA. It was suggested that 5hmC represents an inter-
mediate product in the active DNA demethylation
process possibly following a demethylation mechanism
through the thymidine salvage pathway to repair DNA
alkylation damages [11].
The loss of 5hmC, together with a downregulation or
mutation of TET proteins, have been reported in numer-
ous types of cancer, e.g., melanoma, breast, prostate,
myeloid, brain, and liver cancer [16, 12]. For example,
mutations of TET2 protein have been recorded in pa-
tients with different myeloid malignancies [17–19]. A
number of studies have provided an important link be-
tween TET2 dysfunction, an oncogenic metabolite 2-
hydroxyglutarate (2-HG), myeloid differentiation, and
malignancies [20, 21].
Hepatocellular carcinoma (HCC), which is frequently
caused by a hepatitis virus B and C infection or alcohol
abuse, is the most common type of primary liver cancer
[22, 23]. The mechanisms that lead to HCC develop-
ment are still unclear. Beside many possibilities that may
lead to HCC development, it has been shown that accu-
mulation of genetic abnormalities such as chromosomal
alterations and gene amplifications, mutations along epi-
genetic alterations can trigger HCC development [24].
Recently, a particular focus has been directed towards
abnormal DNA methylation at the fifth position of cyto-
sine (5mC) [25]. Therefore, the detection of DNA
methylation may provide a potential application for the
clinical diagnosis of HCC. Liu and colleagues have re-
ported that a reduction of 5hmC is associated with pro-
gression of liver cancer through downregulation of
TET1 protein [18]. In contrast, Gao et al. have studied
nine samples and reported not only the downregulation
of TET1 but also of TET2 mRNA levels with a concomi-
tant decrease of 5hmC. The researchers, however, found
no change in TET3 expression in hepatocellular carcin-
oma compared to normal liver samples [26]. Moreover,
in another study by Yang et al., the decrease of all three
TET genes was shown in three pairs of frozen human
hepatocellular carcinoma tissue compared to matched
normal liver tissue [27]. Despite accumulating evidence
for the correlation between loss and decrease of 5hmC
and progression of hepatocellular carcinoma, it remains
totally unclear, which of the TET proteins seems to be
responsible for the loss of active demethylation pattern
in HCC.
In contrast to conventional or molecularly targeted
therapies for inhibiting dysregulated genes or signaling
pathways in HCC, epigenetic drugs may provide an al-
ternative approach by reversing the methylation status.
5-Azacytidine is known as a DNA methyltranferase in-
hibitor (DNMTi), which is clinically approved for the
treatment of myelodysplasia syndrome and acute mye-
logenous leukemia (AML) [28, 29]. However, the role of
5-azacytidine in active demethylation pathway is not
clear.
Therefore, because of the apparent debate, which TET
proteins are involved in 5hmC/5mC regulation in HCC,
our primary aim of this study was to identify which TET
protein play a crucial role in the regulation of 5hmC and
5mC in HCC. Furthermore, we wanted to know whether
or not 5-AZA triggers a TET-dependent active demethyla-
tion process in HCC controlling 5hmC/5mC regulation.
Methods
Cell culture medium, DMEM medium, William’s medium
E, and cell culture supplements were purchased from
Sigma-Aldrich (Steinheim, Germany). Cell culture plastics,
phosphate buffered saline (PBS), and fetal calf serum
(FCS) were purchased from PAA Laboratories GmbH
(Pasching, Austria). DNaseI (RNase—free) and first strand
cDNA Synthesis Kit were purchased from Fermantas
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(Ontario, Canada). 5-Azacytidine (SLBH7350V) was ob-
tained from Sigma-Aldrich (Steinheim, Germany). All
other chemical compounds were purchased from Carl
Roth (Karlsruhe, Germany). 5hmC (39769) rabbit pAB
and 5mC (39649) mouse mAB were purchased from Ac-
tive Motif (Carlsbad, CA, USA). Proliferating cell nuclear
antigen (PCNA) (ab92552) rabbit mAB was obtained from
Abcam (Cambridge, UK). Corresponding secondary anti-
bodies goat anti-rabbit Alexa 555 and goat anti-mouse
488 were acquired from Invitrogen (Carlsbad, CA,
USA). Anti-TET2, anti-TET3, and anti-glyceraldehyde
3-phosphate dehydrogenase (GAPDH) antibodies were
used from Sigma-Aldrich (Munich, Germany). The
HRP-linked anti-rabbit IgG secondary antibody was
purchased from Cell Signaling (Beverly, MA, USA).
Tissue samples and primary human hepatocyte isolation
and cell culture condition
Tissue specimens were obtained from patients undergoing
resection of HCC according to the approval of local ethics
committee. A tissue microarray (TMA) containing HCC
samples and their corresponding noncancerous liver tissue
was constructed. Primary human hepatocytes were iso-
lated from human liver tissue according to the institu-
tional guidelines of the Tubingen University from liver
resections of tumor patients with primary or secondary
liver tumor (ethics approval number: 368/2012BO2). The
isolation and purification of primary human hepatocytes
were performed as previously described [30]. Culture con-
dition of HCC cell lines (Huh7, HLE and HLF) and human
primary hepatocytes (hHeps) was published previously [31,
32, 30]. HLE and HLF cells were purchased from ATCC,
and Huh7 was purchased from JCRB (Japanese Collection
of Research Bioresources Cell Bank). The HCC cell lines as
well as hHep were plated onto 6-, 24-, or 96-well plates,
treated for 24 h and subsequently incubated with different
concentrations of 5-AZA (20, 10, 5, 1) for 48 h. Huh7,
HLE, and HLF cells were cultured in DMEM (Lonza Group
Ltd., Cologne, Germany) supplemented with 2 mM glutam-
ine (PAA Laboratories GmbH, Pasching, Austria) and 10 %
FCS (Invitrogen, Darmstadt, Germany) at 37 °C and 5 %
CO2 in a humidified incubator. Experiments were con-
ducted between passage numbers 2 and 12 without full
confluency throughout experiments. Absence of myco-
plasma contamination was confirmed by Venor®GeMtest
(Minerva Biolabs GmbH, Berlin, Germany).
Immunohistochemical staining
Immunohistochemical stains were performed using
3.5 μm sections of TMA. Slides were deparaffinized,
dehydrydrated, and after antigen retrieval were placed in
2 N HCL for 60 min, rinsed with distilled water, and
placed in 100 Mm Tris–HCl (pH 8.5) for 10 min. Tissue
slides were incubated in Dako Dual Endogenous Enzyme
Block (CA, USA) for 10 min. The sections were blocked
in PBS solution containing 10 % FCS and 0.1 % Tween-
20 for 1 h. The section was incubated with either anti-
5hmC rabbit at 1:1000 (active motif, 39769) or anti-5mC
mouse at 1:500 (active motif, 39649) overnight at 4 °C
and then incubated with Plus HRP One-Step Polymer
kit from Zytochem (Berlin, Germany) for 30 min. Tissue
sections were washed and subsequently DAB Substrate
Kit High Contrast from Zytochem (Berlin, Germany) was
used according to the manufacturer’s instruction. After
rinsing, the cells were counterstained with hematoxylin.
Scoring for immunohistochemical staining was performed
by SAS and BS. All specimens were evaluated according
to the 0–4 grading criteria (based on the percentage of
5hmC positive cells) and 0–3 grading criteria (based on
the staining intensity) [33]. The intensity score was multi-
plied with percentage of positive cells of three different
high power fields for each section. The total score was de-
termined from 0 to 12.
Immunofluorescence staining
Cells were plated onto cover slips and treated according to
the experimental setup. Cells were fixed with 4 % parafor-
maldehyde solution for 15 min at RT and then washed with
PBS. For permeabilization, cells were incubated with 0.5 %
Triton-X-100 PBS solution for 15 min at RT. To denature
the DNA, cells were incubated with 4 M HCl for 15 min at
RT, rinsed with distilled water, and placed in 100 mM
Tris–HCl (pH 8.5) for 10 min. After washing with PBS, un-
specific binding sites were blocked with blocking buffer
(10 % FCS, 0.1 % Tween-20 in PBS) for 1 h at RT. Then,
cells were incubated with primary antibodies such as anti-
5hmC rabbit polyclonal IgG (Active Motif, CA, USA), anti-
5mC mouse monoclonal IgG, (Active Motif, CA, USA) or
anti-PCNA Rabbit mAB (Abcam, Cambridge, UK) at
1:1000, 1:400, and 1:200, respectively, in PBS solution con-
taining 1 % FCS and 0.1 % Tween-20 overnight at 4 °C.
After washing with PBS, cells were incubated with second-
ary antibody solution (Alexa-Fluor antibodies, Invitrogen,
NY, USA) diluted 1:400 in PBS solution containing 1 %
FCS, 0.1 % Tween-20 for 1 h at RT. The nuclei were coun-
terstained by incubation with Hoechst 33342 solution
(2 μg/ml in PBS) for 10 min at RT. After a final washing
step with PBS, the stained cells were mounted with mount-
ing medium (Fluoromount G, Southern Biotech, NJ, USA).
Images of the staining were taken with an EVOS fluores-
cence microscope (AMG, Life technologies, MA, USA)
under standardized condition, processed, and analyzed
with Image J 1.45s software (NIH, USA) [34].
RNA extraction, cDNA synthesis, and quantification of
gene expression
Total cellular RNA was isolated with Trifast (Peqlab,
Erlangen, Germany); 2–3 μg of the total RNA was
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digested with DNase I in order to remove remaining
genomic DNA, according to the manufacturer’s instruc-
tions (Fermentas International Inc., Ontario, Canada).
Complementary DNA (cDNA) was synthesized by Re-
vert Aid First Strand cDNA Synthesis Kit (Fermentas
International Inc., Ontario, Canada).
For quantitative real-time PCR (qRT-PCR), 40 ng of
template cDNA was used for the expression level of each
target gene (primer sequences are listed in Table 1)
using SYBR Green qPCR (Thermo scientific, Waltham,
MA, USA) and the Step One Plus® Real-Time PCR Sys-
tem kit (Life technologies, Carlsbad, CA, USA). Among
different existing housekeeping genes (e.g., GAPDH,
ACTB, and B2M), B2M was used as an endogenous con-
trol because of the constant expression of this gene in
hepatocellular carcinoma and normal tissue samples. In
line with our results, Waxman et al. reported the dysreg-
ulation of common housekeeping genes such as GAPDH
and ACTB in hepatocellular carcinoma [35], which may
lead to wrong positive or wrong negative results. In pre-
liminary experiments, we found that the expression of
TET1 was at the detection limit of all liver tissue sam-
ples and HCC cell lines. Therefore, we investigated isoci-
trate dehydrogenase (IDH)1, IDH2, TET2, and TET3 and
not TET1 in our samples. Relative expression values
were calculated from Ct values using the ΔΔCT method
with untreated cells as a control. PCRs were performed
as follows: denaturation for 10 min at 95 °C, amplifica-
tion with 40 cycles and 15 s at 95 °C, 40 s at 60 °C, and
15 s at 72 °C (StepOnePlusTM Real-Time PCR System,
Life technologies, CA, USA). The primer sequences are
listed in Table 1.
Resazurin conversion, LDH leakage, and FACS measurement
To investigate the impact of 5-AZA on cell proliferation,
the cells were incubated with different doses of 5-AZA
at different time points. Cell viability (mitochondrial ac-
tivity) was determined by resazurin conversion. Briefly,
1/10 volume of the resazurin stock solution (0.025 % in
DPBS) was added to the cells. After 30 min of incuba-
tion at 37 °C, fluorescence was measured (Ex/Em = 544/
590 nm) and corrected to background control (solvent
mixture without cells). Viability is given as percentage of
control (untreated cells).
LDH released into cell culture media as index of cell
death was measured using an LDH assay kit from Analy-
ticon (Lichtenfels, Germany) according to the manufac-
turer’s protocol. LDH released into the media was
expressed as the percentage of total cellular LDH per
well measured after cells had been lysed with 1 % Triton
X-100.
Apoptosis was determined by fluorescence-activated
cell sorting (FACS) quantification of hypodiploid cells.
For FACS analysis of sub2N peaks, 1 × 106 HCC cells
per well were seeded in six-well plates and treated with
different concentrations of 5-AZA. After 48 h, cells were
fixed in ethanol and stained in hypotonic solution with
RNase and Propidium Iodid (PI) for 30 min. Hypodip-
loid (sub2N) cells were considered apoptotic [36].
Western blot
HCC cell lines and hHep cells were lysed in ice-cold
RIPA lysis buffer (50 mM Tris, 250 mM NaCl, 2 %
Nonidet-P40, 2.5 mM EDTA, 0.1 % SDS, 0.5 % DOC,
complete protease inhibitor, 1.0 % phosphatase inhibitor,
pH 7.2). Protein concentration was determined by micro-
Lowry. Fifty micrograms of total protein was separated by
SDS-PAGE and transferred to nitrocellulose membranes
(Roth, Karlsruhe, Germany). The membranes were
blocked by 5 % BSA solution for 2 h and incubated over-
night with rabbit polyclonal primary antibodies (TET2,
TET3, and GAPDH) (TET2, TET3 antibodies prepared
1:500 and GAPDH 1:10,000 in 5 % w/v BSA 1× TBS,
0.1 % Tween-20) (Sigma Aldrich, Munich, Germany) at
4 °C. The following day membranes were incubated with
the corresponding HRP-labeled secondary antibodies for
2 h at RT. Chemiluminescent signals were detected with
the ChemoCam (INTAS, Gottingen, Germany).
Protein depletion by short interference RNAs
For depletion of TET2 and TET3, the siRNAs were or-
dered from Eurofins MWG Operon (Ebersberg, Germany)
and upon arrival tagged with fluorochrome. The short
interference RNAs (siRNAs) were transfected with
Table 1 Sequences of primers used in qPCR
Gene bank ID Forward primer Reverse primer Product length (bp)
TET1 NM_030625.2 TCTGTTGTTGTGCCTCTGGA GCCTTTAAAACTTTGGGCTTC 77
TET2 NM_001127208.2 GAGACGCTGAGGAAATACGG TGGTGCCATAAGAGTGGACA 258
TET3 NM_001287491.1 CCCACAAGGACCAGCATAAC CCATCTTGTACAGGGGGAGA 129
IDH1 NM-001282387.1 TCCGTCACTTGGTGTGTAGG GGCTTGTGAGTGGATGGGTA 128
IDH2 NM-002168.3 TGAACTGCCAGATAATACGGG CTGACAGCCCCCACCTC 121
GAPDH NM_002046.4 TGCACCACCACTGCTTAGC GGCATGGACTGTGGTCATGAG 87
B2M NM_004048.2 AGATGAGTATGCCTGCCGTG GCGGCATCTTCAAACCTCC 105
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lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA). The
cells were seeded in six-well plates at the density of 2 ×
105 in 2 ml medium. siRNAs were transfected with lipo-
fectamine reagent according to the manufacturer’s in-
structions. The final siRNAs concentration was 50 nM.
Untreated cells and cells treated with 5-AZA were har-
vested after 48 h. The scrambled siRNA for negative con-
trol experiments were also obtained from Eurofins. The
efficiency of transfection was measured by flow cytometry,
and the efficiency of transfection was approximately
around 70–80 % for each siRNAs in the HCC cell lines
(data was not shown). The siRNA sequences are listed in
Table 2.
Statistical analysis
Statistical significance of differences between the individ-
ual treatments was evaluated by Student’s t test, one-way
ANOVA, and whisker (Prism 5.01, GraphPad Software,
San Diego, USA). Data are means ± SEM of three to five
independent experiments. All statistical comparisons
were performed two-sided in the sense of an exploratory
data analysis using 0.05 (*), 0.01 (**), and 0.001 (***) level
of significance.
Results
5hmC is decreased in human HCC tissues and cell lines
The genomic distribution of 5hmC and 5mC in tissue-
microarray-paraffin-embedded tissues and cells was evalu-
ated by immunohistochemistry and immunofluorescence
staining. When evaluating 55 HCC tissue samples, a sig-
nificant (p < 0.001) decline of 5hmC (quantified via IHC,
Fig. 1a) along with a significant (p < 0.001) increase of
5mC as compared to noncancerous liver tissue of the
same patient (Fig. 1a) was observed in HCC liver samples.
These results were confirmed in HCC cell lines showing a
reduction of 5hmC as compared to primary human hepa-
tocytes with immunofluorescence staining for 5hmC
(Fig. 1b). These results are in line with previous reports
demonstrating loss of 5hmC in various types of cancers,
including HCCs [16, 18, 37].
Reduction of 5hmC correlates with decreased TET2 and
TET3 gene expression in HCC tissues and cell lines
To understand which important cellular factors are
responsible for 5hmC reduction in HCCs, we deter-
mined the expression of IDH1, IDH2, TET1, TET2,
and TET3 by qRT-PCR. Despite others have reported
that TET1 is downregulated in HCC tissue compared
with ‘normal’ liver tissue [18, 27], we found no TET1
expression by qRT-PCR in normal adult human liver
tissue, HCC tissue as well as HCC cell lines or hu-
man hepatocytes (data not shown). In contrast, we
found that the expression of both TET2 and TET3 as
well as the upstream genes IDH1 and IDH2 were sig-
nificantly decreased in human HCC tissues as com-
pared to matched “normal” liver tissues (Fig. 2a).
These data were confirmed in HCC cell lines (Huh7,
HLE, and HLF) compared with freshly isolated pri-
mary human hepatocytes (Fig. 2b).
Effect of 5-azacytidine on HCC cells proliferation and
viability
Incubation of the three tested HCC cell lines with 5-
AZA showed a dose- and time-dependent reduction of
mitochondrial activity, as measured by resazurin conver-
sion (Fig. 3a). To strengthen this result, the effect of
AZA on cell proliferation was additionally tested analyz-
ing the proliferation cell nuclear antigen (PCNA) IF [38],
showing a significant decrease nuclear staining com-
pared to untreated cells (Fig. 3b). Altogether, our data
show that incubation of HCC cells with 5-AZA inhibited
proliferation in a dose-dependent manner in all tested
HCC cell lines which is paralleled by an increased LDH
release in HLF and HLE (Fig. 3c). Further analyses re-
vealed that 5-AZA induced apoptosis to a certain extent
in all tested HCC cell lines (Fig. 3d).
5-Azacytidine triggers active demethylation in HCC cells
It is known that 5-AZA induces passive demethyla-
tion through inhibition of DNMT [39]; however, it is
not known to our knowledge if it has an influence
on active demethylation through induction of TET
expression. Treatment of HCC cell lines (Huh-7,
HLE, and HLF) with 5-AZA for 24 and 48 h led to
a significant increase in 5hmC-positive cells com-
pared to untreated HCC cells (Fig. 4a). To further
investigate a potential active demethylation process
through converting 5mC to 5hmC, the expression of
TET2 and TET3 was determined. 5-AZA-stimulated
cells displayed significantly increased expression of
TET2 and TET3, while the expression of IDHs is not
influenced (Fig. 5a, c). Increased expression of TET2
Table 2 Oligonucleotide sequences for siRNA primers
Gene Name Target sequence 5′ or 3′ Mod
Control Scrambled siRNA 5′AACAGTCGCGTTTGCGACTGG3′ 3′ FLU
TET2 TET2-siRNA 5′CAAGACCAATGTCAGAA 3′ 3′ FLU
TET3 TET3-siRNA 5′GATGAAGGTCCATATTA 3′ 5′ CY3
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and TET3 upon 5-AZA treatment was confirmed by
Western blot analysis (Fig. 5b). We next needed to
functionally prove if 5-AZA treatment in line with
our previous work could trigger oxidation of 5mC to
5hmC through the induction of TET2 and/or TET3
expression [40] in HCC. If this would be the case,
we would have strong evidence of an active
demethylation process caused by 5-AZA. We were
able to demonstrate that the conversion of 5mC to
5hmC upon 5-AZA treatment depends on TET pro-
teins by simultaneous knockdown of TET2 and TET3
expression in Huh-7, HLE, and HLF cells, using
siRNA. mRNA levels of the TET genes could be
downregulated to approximately 30 % for TET2 and
Fig. 1 Distribution of 5-hydroxymethylcytosine (5hmC) and 5-methylcytosine (5mC) in HCC tissue. a IHC was performed using antibodies against
5hmC and 5mC in human normal and HCC tissues, the mean values of the IHC are shown (each group N = 55, n = 3). Four pictures are presented
for each condition. The reduction of the 5hmC generation and an increase of 5mC in HCC samples compared with the corresponding normal
liver samples were observed. Data are represented as box plot (whisker, Tukey). b IF staining was performed by using the antibody against 5hmC
(red) for HCC cell lines (Huh7, HLE, and HLF). Cell nuclei were counterstained with Hoechst 33342 (blue). Scale bar are 20 μM. For quantification,
5hmC positive nuclei were counted. Statistical methods included paired t test and independent samples t test. All statistical tests were considered
significant at α = 0.05 (p < 0.05)
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40 % for TET3, as compared to corresponding trans-
fected cells with control siRNAs (Fig. 6a). In control
cells, TET2 and TET3 mRNA knockdown decreased
intrinsic 5hmC levels. Upon TET2 knockdown, 5-
AZA (20 μM) treatment was unable to enhance the
generation of 5hmC. In contrast, 5-AZA still enhan-
ced—although to a much lesser extent—the expres-
sion of 5hmC in TET3 knocked-down HCC cells
(Fig. 6b). Overall, these results suggest that the
enhancing effect of 5-AZA on 5hmC generation in
HCC is mainly mediated by TET2.
Discussion
Changing the balance of DNA methylation and de-
methylation related to epigenetic modification has be-
come a main interest of cancer research in recent
years [41]. The loss of 5hmC as a demethylation
marker has been suggested as prognostic marker in
Fig. 2 Reduction of 5hmC is associated with the substantial reduction of IDH1 and IDH2 and TET2 and TET3 gene expressions. a The expression
of TET2, TET3, IDH1, and IDH2 decreased in HCC tissues in comparison to the matched normal liver. Real-time qRT-PCR was used to determine
TETs and IDHs relative mRNA levels in HCCs while using β2M as an internal control for normalization. Data are expressed as fold change in
mRNA expression compared to the normal liver control (indicated by dashed line at 1) The data are presented as box plot (N = 9, n = 3):
center line represents the median, box limits represent the first and third quartiles, and whiskers represent 1.5 times the interquartile range (The p value
were assessed by Student’s t test; bars show mean ± SE; p < 0.0001 for TET2, TET3, IDH1, and p = 0.0275 for IDH2). b The same pattern was confirmed
by comparing HCC cell lines (Huh7, HLE, HLF) to primary human hepatocytes (N = 4, n = 3). (p value assed by one-way ANOVA; bars show
mean ± SE) (p < 0.001)
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various types of cancer and even to play a crucial role
in the pathogenesis of cancers [42–44]. It was re-
ported that 5hmC, in addition to its role in DNA de-
methylation via TET proteins, has a role in the
regulation of genes involved in development, pluripo-
tency, and the regulation of RNA splicing processes
[45, 40]. It was shown that 5hmC is a major epigen-
etic modification mark in an adult human liver, play-
ing an important role in hepatic gene expression
changes in hepatocytes [46, 47]. In our study, we
demonstrated that the generation of 5hmC is signifi-
cantly reduced in hepatocellular carcinoma tissues
and cell lines compared with healthy liver tissue and
human hepatocytes. In line with other papers, our
data clearly support the link between 5hmC ablation
and tumor development [48, 49]. Furthermore, our
study indicates that 5mC levels are induced in HCC
tissues as well as cell in HCC cell lines. Altogether,
our study confirms that detection of 5hmC could be
a crucial diagnostic marker for HCCs.
TET proteins (TET1, TET2, and TET3) mediate the
oxidation of 5mC to 5hmC. TET proteins were identi-
fied as dioxygenases that utilize two substantial factors:
Fe(II) and 2-oxyglutarate (2-OG), in order to oxidize the
methyl group (CH3) of 5mC, and to form 5hmC, thereby
mediating active DNA demethylation [9, 14, 28, 50]. The
(See figure on previous page.)
Fig. 3 Distinct effect of 5-AZA on HCC cell lines viability, proliferation and apoptosis. a 5-AZA treatment reduced resazurin conversion in HCC cell
lines (Huh7, HLE, and HLF). The mitochondria activity of cells decreased upon treatment with 5, 10, and 20 μM of 5-AZA for 24, 48, 96, and 120 h
in time- and dose-dependent manner (N = 4, n = 3). b Twenty micromolars of 5-AZA inhibited the PCNA expression in HCC cell lines after 48 h of
incubation. c Twenty micromolars of 5-AZA caused LDH release in HLE and HLF cells after 48 h; however, LDH released in culture supernants by
Huh7 cells did not increase upon treatment 5-AZA after (N = 4, n = 3). d 5-AZA induced cell death in HLE and HLF cells. Determination of sub2N
fractions as marker for apoptosis was measured after treatment of HCC cells with 20 μM 5-AZA for 48 h (p value assed by Student’s t test; bars
show the mean ± SE of three independent experiments)
Fig. 4 5-AZA enhanced the generation of 5hmC in HCC cell lines. a Immunostaining showed that 20 μM of 5-AZA enhances the generation of
5hmC in HCC cell lines after 48 h. b The semi-quantitative analysis of immunofluorescence staining indicated that the incubation of HCC cells
with 5-AZA for 48 h increased 5hmC level (p value assessed by Student’s t test; data are represented as mean ± SE)
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expression of these three TETs varies not only in differ-
ent organs but also in the development of organs [4, 14].
In various tumor types, a different TET family member
has been reported to function as tumor suppressor [5–
8]. Thereby, identification of the most effective TET
protein leading to cancer in the corresponding tissue
is a crucial topic to be investigated in different tu-
mors. Recent evidence suggests that there is a re-
markable correlation between decreased 5hmC levels
and TET expression, resulting in progression of tumor
and metastasis, suggesting that TET proteins might
serve as a tumor suppressor in certain cancer types
[37, 51]. Recently, it was reported that the gene en-
coding TET2 but not TET1 and TET3 was frequently
mutated, and it was identified as the relevant tumor
suppressor gene, which is mutated in leukemia [17].
However, in breast cancer, low expression of TET1
correlated with advanced cancer stage [52]. Further-
more, in some cancer types like colorectal cancer
(CRC), the reductions of all three TET proteins have
been reported [11, 53]. In addition, it was shown that
IDH1 or IDH2 mutations could also result in the re-
duction of 5hmC in cancers [16, 33, 54]. In HCCs,
however, the published results are contradicting each
other regarding the role of TETs. Liu et al. reported
that a reduction of 5hmC is associated with the
downregulation of the TET1 protein in HCC [18]
while Gao et al. claimed a downregulation of TET1
and TET2 but no change in TET3 gene expression
with a concomitant decrease of 5hmC in HCC [26].
Moreover, Yang et al. reported the decrease of all
three TET genes in HCC; however, this group investi-
gated only three pairs of frozen human hepatocellular
carcinoma tissue compared to matched normal liver
tissue [27]. In our study, we clearly found that only
TET2 and TET3 genes are significantly reduced in
HCC tissue and in hepatocellular carcinoma cell lines.
These changes were paralleled by a concomitant de-
crease of IDH genes and 5hmC and a significant
increase of 5mC. The change in 5hmC and 5mC gen-
eration is confirmed by all papers [18, 26, 27], includ-
ing our own results. But what may be the reasons for
these conflicting results? Recently, it was shown that
TET1 plays a crucial role in the early development
process in self-renewal pattern in embryonic stem
cells [4, 14] suggesting a more crucial role for TET1
in embryogenesis. Another hypothesis explaining the
differences may be the infiltration of the so-called
cancer stem cells with an embryonic pattern, which
might be responsible for differences seen in TET1 ex-
pression [55]. Another explanation could be simply
the use of specific analytical tools. It has been re-
ported that the expression of typical housekeeping
genes including glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH) and beta-actin (ACTB) can be affected
through HCC development, and these housekeeping genes
are expressed significantly different in HCC compared to
normal liver tissue [35]. The use of instable genes for
normalization may lead to an over- or underestima-
tion of the fold changes or to misinterpretation of the
results [35].
It is well established that 5-AZA causes the reduction
of the DNA methylation status by inhibiting DNMT
through passive demethylation pathway [56]. Recently,
the active demethylation of DNA through oxidation of
5mC to 5hmC mediated by TET proteins was discovered
[9]. To our knowledge, our study is the first to demon-
strate that 5-AZA reduces the methylation status of
DNA not only by triggering the passive demethylation
pathway of DNA [56] but also the active demethylation
pathway through converting 5mC to 5hmC by inducing
TET2 and TET3 proteins. However, our results showed
that 5-AZA was unable to induce the 5hmC in TET2
knocked-down HCC cell lines suggesting a crucial role
for TET2 in 5hmC induction and in the pathogenesis of
HCC. This was further underlined by our findings that
5-AZA stopped HCC tumor cell growth through de-
cline of 5mC and a strong increase of 5hmC. How-
ever, a detailed mechanism of how 5-AZA affects the
expression and activity of TET proteins remains to be
further elucidated.
Conclusions
The data presented here indicate that a drop of TET2
and TET3 expression and activity as well as IDHs is im-
paired in hepatocellular carcinoma with a concomitant
reduction of 5hmC. Therefore, epigenetic drugs that me-
diate the conversion of 5mC to 5hmC through modulat-
ing TETs and/or IDHs activity may find broad use in the
treatment of HCCs.
(See figure on previous page.)
Fig. 5 5-AZA enhanced the generation of 5hmC through induction of TETs expression in HCC cell lines. a Twenty micromolars of 5-AZA induced
the expression of TET2 and TET3 in HCC cells after 48 h of incubation. The m-RNA level of TET2 and TET3 genes were determined by quantitative
real-time PCR after 24 and 48 h (p value assed by one-way ANOVA; data represented as mean ± SE). b Expression of TET2 and TET3 was examined
by Western blot analysis in HCC cell lines (Huh7, HLE, and HLF) after treatment with 20 μM 5-AZA for 24 and 48 h. c Twenty micromolars of 5-AZA did
not influence the expression of IDH1 and IDH2 in HCC cells significantly after 48 h of incubation. Real-time qRT-PCR was used to determine TETs and
IDHs relative mRNA levels in HCC cell lines while using GAPDH as an internal control for normalization
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This study identified a novel function of 5-azacytidine
in promoting a TET-mediated generation of 5hmC sug-
gesting that the availability of 5-AZA in cancer cells will
have various effects on different epigenetic targets.
Abbreviation
5-AZA: 5-azacytidine; 5caC: 5 carboxylcytosine; 5fC: 5 formylcytosine; 5hmC: 5
hydoxymethylcytosine; 5mC: 5 methylcytosine; CRC: colorectal cancer; h: hours;
HCC: hepato cellular carcinoma; hHep: human primary hepatocyte; IDH: isocitrate
dehydrogenase; IF: immunofluorescence; IHC: immunohistochemistry;
PCNA: proliferating cell nuclear antigen; siRNA: short interference RNA;
TET: ten-eleven translocation.
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